• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022
 

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

on

  • 626 views

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the ...

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is diagnosis.

Annualized market revenues data for 9 key markets: US, France, Germany, Italy, Spain, UK, Japan, China, and India
Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes

Statistics

Views

Total Views
626
Views on SlideShare
626
Embed Views
0

Actions

Likes
0
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022 PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022 Document Transcript

    • PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. Morenotably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammationassociated with the disease. That said, physicians suggest that the largest unmet need for DES treatment isdiagnosis.ScopeAnnualized market revenues data for 9 key markets: US, France, Germany, Italy, Spain, UK, Japan, China,and India Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022 Pipelineanalysis data providing a split across the different phases, mechanisms of action being developed andemerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes Analysis of keyrecent licensing and partnership agreements in the DES Therapeutics market Insightful review of the keyindustry drivers, restraints and challenges. Each trend is independently researched to provide a qualitativeanalysis of its implications Key topics covered include strategic competitor assessment, marketcharacterization, unmet needs and implications.Market Model FeaturesAn interactive excel forecast model based on primary research interviews and surveys with KOLs andhigh-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, ourmodels support data presented in the reports and the complete methodology is outlined in the report and themodel.*Model only available with site and global license purchases.Key FindingsThe global DES therapeutics market is forecast to reach $5.47 billion by 2022 due to the launch of novelpipeline drugs and an aging population. The global push for increased physician and patient awareness willincrease diagnosis and treatment. By 2022, the DES market will be significantly more competitive, but thecurrent dearth of treatment options leave much room for the coming pipeline therapies.Key Questions Answered in this ReportHow will the patent expiry of Restasis affect the competitive landscape? What are the regional differences inDES treatment? What are the drivers for growth in the DES market? Who is the frontrunner in the drugpipeline for DES and what are its strengths and weaknesses? Will pipeline drugs find acceptance in the currenttreatment paradigm? Where are companies investing R&D in 2013?Key BenefitsDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products andtechnologies and by identifying the companies with the most robust pipeline. Develop business strategies byunderstanding the trends shaping and driving the global market. Drive revenues by understanding the keytrends, innovative products and technologies, market segments and companies likely to impact the market infuture. Formulate effective sales and marketing strategies by understanding the competitive landscape and byanalyzing the performance of various competitors. Identify emerging players with potentially strong productPharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022
    • portfolios and create effective counter-strategies to gain a competitive advantage.table Of Contents1table Of Contents11.1list Of Tables51.2list Of Figures62executive Summary82.1significant Growth Is Expected In The Des Market From 2012-2022.82.2established Players Lack Strong Pipelines And Will Focus On Filling This Gap Through Acquisitions102.3with Only One Drug On The Market In The Us And Two In Japan, There Is A Significant Void To FulfillWith Pipeline Products102.4the Real Opportunity For New Players To Market Their New Products And Expand The Patient BaseRelies On Improved Diagnosis.112.5pipeline Agents Offer Patients Expansion Into New Markets, Novel Mechanisms Of Action AndLonger-acting Delivery Systems.112.6what Do The Physicians Think?123introduction143.1catalyst143.2related Reports144disease Overview154.1etiology And Pathophysiology154.1.1etiology154.1.2pathophysiology164.1.3classification194.1.4prognosis194.1.5quality Of Life204.2symptoms205epidemiology215.1risk Factors And Comorbidities215.1.1risk Of Dry Eye Syndrome Increases 35% Each Decade After Age 40225.1.2women Are Twice As Likely To Have Dry Eye Syndrome As Men225.1.3use Of Certain Medications May Increase The Risk Of Developing Dry Eye Syndrome235.1.4diets Rich In Omega-3 Fatty Acids Help Prevent Dry Eye Syndrome24PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022
    • 5.1.5certain Environmental Conditions Can Double The Risk Of Dry Eye Syndrome245.2global Trends245.2.1us245.2.25eu255.2.3asia255.3forecast Methodology265.3.1sources Used265.3.2forecast Assumptions And Methods275.3.3sources Not Used295.4epidemiology Forecast (2012–2022)305.4.1prevalent Cases Of Dry Eye Syndrome305.4.2age-specific Prevalent Cases315.4.3sex-specific Prevalent Cases345.4.4age-standardized Prevalence Of Dry Eye Syndrome355.5discussion365.5.1conclusions On Epidemiology Trends365.5.2limitations Of The Analysis395.5.3strengths Of The Analysis396disease Management396.1overview396.1.1diagnosis Overview396.1.2treatment Guidelines436.1.3treatment Overview476.2us506.2.1diagnosis506.2.2clinical Practice516.3france526.3.1diagnosis526.3.2clinical Practice536.4germany546.4.1diagnosis546.4.2clinical Practice546.5italy546.5.1diagnosis546.5.2clinical Practice546.6spain566.6.1diagnosis566.6.2clinical Practice566.7uk576.7.1diagnosis576.7.2clinical Practice57PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022
    • 6.8japan576.8.1diagnosis576.8.2clinical Practice586.9china606.9.1diagnosis606.9.2clinical Practice606.10india616.10.1diagnosis616.10.2clinical Practice617competitive Assessment627.1overview627.2strategic Competitor Assessment627.3product Profiles – Major Brands637.3.1restasis (cyclosporine 0.05% Ophthalmic Emulsion)637.3.2diquas (diquafosol Tetrasodium)697.3.3mucosta (rebamipide 2% Ophthalmic Suspension)727.3.4additional Therapies758opportunity And Unmet Need788.1overview788.2diagnostic Tests Are Not Specific Enough To Identify Subgroups Of Patients808.3frequent Dosing And Side Effects Limit Compliance818.4lack Of Physician And Patient Awareness828.5trial Design May Be A Factor In So Few Drugs Being Approved838.6unmet Needs Gap Analysis848.7comprehensive Method For Measuring Dry Eye Signs And Severity Levels858.8increase Treatment Rates Among Milder Forms Of The Disease869pipeline Assessment869.1overview869.2clinical Trial Mapping879.2.1clinical Trials By Country879.2.2clinical Trials By Phase And Trial Status889.3promising Drugs In Clinical Development889.3.1lifitegrast909.3.2cf-101949.3.3cyclokat979.3.4egp-4371019.3.5rx-10045105PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022
    • 9.3.6mim-d310910current And Future Players11210.1overview11210.2trends In Corporate Strategy11410.3company Profiles11510.3.1allergan11510.3.2alcon (a Wholly-owned Subsidiary Of Novartis Ag)11710.3.3santen Pharmaceutical11810.3.4shire/sarcode Bioscience12310.3.5otsuka Holdings12410.3.6can-fite Biopharma12610.3.7eyegate Pharma12811market Outlook12911.1global Markets12911.1.1forecast12911.1.2drivers And Barriers – Global Issues13111.2united States13311.2.1forecast13311.2.2key Events13611.2.3drivers And Barriers13711.3france14011.3.1forecast14011.3.2key Events14111.3.3drivers And Barriers14111.4germany14411.4.1forecast14411.4.2key Events14611.4.3drivers And Barriers14611.5italy14811.5.1forecast14811.5.2key Events15011.5.3drivers And Barriers15011.6spain15211.6.1forecast15211.6.2key Events15411.6.3drivers And Barriers15411.7united Kingdom15411.7.1forecast15411.7.2key Events157PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022
    • 11.7.3drivers And Barriers15711.8japan15911.8.1forecast15911.8.2key Events16111.8.3drivers And Barriers16111.9china16311.9.1forecast16311.9.2key Events16511.9.3drivers And Barriers16511.10india16711.10.1forecast16711.10.2key Events16811.10.3drivers And Barriers16812appendix16912.1bibliography16912.2abbreviations17712.3methodology17812.4forecasting Methodology17812.4.1diagnosed Des Patients17812.4.2percent Drug-treated Patients18012.4.3drugs Included In Each Therapeutic Class18012.4.4launch And Patent Expiry Dates18012.4.5general Pricing Assumptions18012.4.6individual Drug Assumptions18212.4.7generic Erosion18512.5physicians And Specialists Included In This Study18612.6about The Authors18712.6.1author18712.6.2epidemiologist18812.6.3reviewers18912.6.4global Director Of Epidemiology And Clinical Trials Analysis19012.6.5global Head Of Healthcare19112.7about Globaldata19212.8contact Us19212.9disclaimer192ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market researchreports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with ourhuge collection of market research reports. We provide our services to all sizes of organizations and across allindustry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well aspublishers and will assist you in making an informed decision by giving you unbiased and deep insights onPharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022
    • which reports will satisfy your needs at the best price.Contact:M/s Sheela,90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usWebsite: http://www.researchmoz.us/PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022